Kornimate/medical-research-clean huggingface dataset:
long-term outcomes of children with congenital cmv in new york state

Conditions: Congenital CMV Infection; Sensorineural Hearing Loss

Summary: proactive nys is a long-term follow-up study of all infants who test positive for congenital cytomegalovirus infection (cmv) throughout new york state on the newborn screen. by following all infants who screen positive, we will learn important information about the range of symptoms caused by congenital cmv, from those babies with more severe findings to those with no symptoms. in particular, our study will provide new information about many facets of congenital cmv, including: * developmental, hearing, neurologic, and vision outcomes * the spectrum and timing of symptoms * the impact congenital cmv has on the baby and its family * how many babies are infected with congenital cmv in new york state how antiviral medications and other interventions impact outcomes of children with congenital cmv throughout the duration of the study, children will undergo routine developmental and hearing assessments, which will assist with early diagnosis of any infection complications. any child found to have a neurodevelopmental, hearing, or vision abnormality will be referred for appropriate evaluation and treatment. families will also be asked to complete periodic surveys about their experience with congenital cmv, both as a medical diagnosis and as it affects their day-to-day activities.


Eligibility criteria:
inclusion criteria: * neonates born in new york state during ccmv nbs pilot program (september 27, 2023 - october 1, 2024) * ccmv evaluation provided by a designated nys ccmv clinical referral site * family willing and able to complete all study procedures * study participants meet criteria for one of the following four categories: * 1. category 1 (confirmed ccmv identified by nbs program): ccmv nys newborn screen positive and ccmv confirmatory test positive * 2. category 2 (confirmed ccmv not identified by nbs program): ccmv nys newborn screen negative and ccmv confirmatory test positive * 3. category 3 (false-positive ccmv screen): ccmv nys newborn screen positive and negative ccmv confirmatory test * 4. category 4 (premature infants with confirmed cmv infection on late positive nbs): infant born prior to 37 weeks gestation and ccmv positive on any nys newborn screen collected prior to 44 weeks gestational age and positive ccmv confirmatory test obtained within 14 days of a positive nbs exclusion criteria: * neonate whose parents refuse participation in the long-term follow-up study

Keywords: congenital cmv ccmv congenital infection sensorineural hearing loss snhl
enhanced metal reduction techniques for definitive ct scanning to assess spinal fusion with tm-ardis

Conditions: Degenerative Disc Disease

Summary: to determine if the subject metal reduction software helps to better visualize bone interphase and fusion reliability. assess whether the appropriate procedural modification facilitates clearer images when implanted with a trabecular metal spinal implant

to determine if the subject metal reduction software helps to better visualize bone interphase and fusion reliability, and assess whether the appropriate procedural modification facilitates clearer images when implanted with a trabecular metal spinal implant.

Eligibility criteria:
inclusion criteria: * a signed informed consent. * male or non-pregnant female scheduled for trabecular metal (tm - ardis) implant, single level lumbar. * participant must be at least 18 years of age. exclusion criteria: * patient is pregnant patient is unable to comprehend the requirements of the study. * patient is unable to undergo scanning (due to body habitus, inability to comply with positioning requirements, etc.).

Keywords: trabecular metal metal reduction ct tm- ardis
the mechanism of sox4 transcription in regulation of angiogenesis in hepatocellular carcinoma

Conditions: Translational Research of SOX4 in Hepatocellular Carcinoma

Summary: two hundred hcc patients with partial hepatectomy were enrolled as a cohort for observational study. the inclusion criterion was intended curative hepatectomy for hcc patients by image analysis, and the exclusion criteria were unresectable disease, synchronous cancers, recurrent cancers, or distant metastasis. the study endpoint was 30 march 2019, and tumor staging was based on the 8th edition of the american joint committee on cancer (ajcc) tnm staging system for hcc

to determine the role of sox4 in tumor progression in patients with hcc, we examined sox4 expression through immunohistochemistry (ihc) staining of 200 formalin-fixed and paraffin-embedded (ffpe) hcc specimens . the sox4 high group of patients was associated with positive etiology of hepatitis b virus (p = 0.044), tumor size \>5 cm (p = 0.014), thrombus formation (p = 0.012), higher microvessel density (mvd) (p = 0.012) in tumor lesions, and distant metastasis (p \<0.001). cox regression analysis showed that patients with elderly age (p \<0.001), higher ⍺-fetal protein (afp) (p = 0.045), presence of cirrhosis (p = 0.008), and sox4 high in tumor specimen (p = 0.042) were independent risk factors . the sox4 high group performed significantly worse regarding overall survival (os) (p = 0.043) and disease-free survival (dfs) (p = 0.019) based on the kaplan-meier analysis.

Eligibility criteria:
inclusion criteria: subjects with pathologic diagnosis of hepatocellular carcinoma and curative partial hepatectomies - exclusion criteria: history of different malignant disease, subject cannot be treated with curative surgery -

Keywords: sox4 angiogenesis microvessel density
a double-blind, double dummy, randomized comparison study of the efficacy and safety of valdecoxib 10mg once daily and naproxen 500mg twice daily in treating the signs and symptoms of osteoarthritis of the knee or hip in taiwan

Conditions: Osteoarthritis

Summary: to evaluate the efficacy, safety, and tolerability of valdecoxib by comparing valdecoxib 10 mg daily (qd) with naproxen 500 mg twice daily (bid) in treating the signs and symptoms of osteoarthritis (oa) of the knee or hip. the study was designed to collect comparative information for the local population (taiwan).


Eligibility criteria:
inclusion criteria: * the diagnosis of hip oa, which was having hip pain and meeting criteria for at least 2 of the following: a. westergren erythrocyte sedimentation rate of \< 20 mm/hr; b. radiographic femoral or acetabular osteophytes or c. radiographic joint space narrowing * knee oa diagnosis required diagnosing (by modified american college of rheumatology criteria) oa of the knee with pain plus at least one of the following: a. age\> 50 years old, b. stiffness \< 30 minutes, c. crepitus on active motion and radiographic evidence of oa of the knee, defined as presence of osteophytes or joint space narrowing * symptomatic oa of the knee or hip was determined at the baseline visit, if the patient's assessment of arthritis pain was at least 40 mm vas, patient's and the physician's global assessment of arthritis was "poor" or "very poor" exclusion criteria: * use of nsaids or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) before baseline arthritis assessments

Keywords: osteoarthritis, knee osteoarthritis, hip
bioavailability study of pf-00868554 administered as 3x250mg oral tablets (wet granulate, 3x250mg oral tablets (dry granulate) and 750mg solution under fed state

Conditions: Hepatitis C Virus

Summary: this study will test two different formulations. the results will be used to select formulation for phase 3.


Eligibility criteria:
inclusion criteria: * healthy volunteers. exclusion criteria: * standard for healthy volunteers.
impact of xdemvy® on demodex blepharitis in soft contact lens wearers

Conditions: Demodex Blepharitis

Summary: to compare the efficacy of xdemvy ophthalmic drop to its vehicle control for the treatment of demodex blepharitis and its impact on the soft contact lens wearing experience.

this phase 4 study is a prospective, multicenter, randomized, vehicle-controlled, double-masked, two-arm, parallel treatment clinical trial of participants who have demodex blepharitis and are current daily wear soft contact lenses wearers. the primary outcome measure is the reduction of collarettes at day 43. the secondary outcome measures are the reduction of eyelid margin erythema at day 43; subject-reported comfortable contact lens daily wear time; and total contact lens wear time. safety will be determined by assessing adverse effects related to study drug administration as well as evaluating any clinically significant changes from baseline in visual acuity and slit lamp biomicroscopy findings.

Eligibility criteria:
inclusion criteria: * be willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol * must meet the following criteria in at least one eye: have more than 10 eyelashes (grade 2 or higher) with collarettes on the upper or lower eyelid; have at least grade 1 erythema of the lower eyelid; and have a total meibomian gland secretion score ≥ 12 but ≤ 32 and have a minimum of 6 expressible glands for the 15 glands evaluated on the lower eyelid * currently wearing soft contact lenses on both eyes an average of at least 2 days per week with an average minimum wearing time of 6 hours each day over the past 3 months and is able and willing to continue to wear contact lenses during the study exclusion criteria: * use of artificial tears or rewetting drops within 24 hours of the screening visit or unwilling to forego the use of this treatment during the study * prescription and systemic, drug delivery implant, ocular topical, or topical: antibacterial, anti-parasitic, or anti-inflammatory corticosteroid treatment within 14 days of the screening or day 1 visits * use of tyrvaya™ nasal spray (varenicline solution, oyster point pharma) within 14 days of the screening visit or unwilling to forego the use of this treatment during the study * use of xdemvy™ (lotilaner ophthalmic solution) 0.25%, tarsus pharmaceuticals, inc., within 12 months of the screening visit * treatment for blepharitis (e.g., tea tree oil-based products, hypochlorous acid-based products, commercial eyelid foams, eyelid wipes, lid scrubs, etc.) within 14 days of the screening visit or unwilling to forego the use of these treatments during the study * use of artificial eyelashes or eyelash extensions at the screening visit if they limit accurate eyelid margin assessment * currently pregnant or lactating

Keywords: soft contact lenses
assessment of knee flexor muscles strength in patients with patellar instability

Conditions: Patella Dislocation Recurrent; Children, Only

Summary: the study enrolled 33 patients with confirmed recurrent patellar dislocation, including 6 patients with bilateral involvement. in the study group, both side hamstring muscle were evaluated at the velocities of 60 and 180 deg/s for the following parameters: peak torque, torque in 30 degree of the knee flexion, angle of peak torque and peak torque hamstring to quadriceps ratio (h/q ratio).

the study enrolled 33 patients with confirmed recurrent patellar dislocation, including 6 patients with bilateral involvement. the study group consisted of 20 girls and 13 boys with average age at the time of the study 16.2 years (range: 8 to 17 years, sd 2.7). for the purpose of the study, a control group of 18 healthy subjects (12 girls and 6 boys) aged on the average 15.7 years (range:13 to 17 years, sd 1.5), was recruited. the following study inclusion criteria were applied: recurrent patellar dislocation, correctly completed testing protocol, age under 18 years at the time of testing. subjects with osteochondral fracture and those with a history of the knee surgery were excluded. each patient underwent an isokinetic examination on biodex system 3 (biodex multi-joint system - pro, biodex medical systems, inc. new york, usa). in the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (pt), torque in 30 degree of the knee flexion (t 30 deg.), angle of peak torque (apt) and peak torque hamstring to quadriceps ratio (h/q ratio). isokinetic measurements were made by a trained, experienced physiotherapist. after a proper warm-up and instruction, the test performed 10 full repetitions, the best result was recorded. the results of the peak torque (pt) of both test and control limbs were then compared with the normative data for age and gender available in the literature. in addition, we compared the peak torque (pt), torque in 30 degrees of the knee flexion (t 30 deg.), angle of peak torque (apt) and peak torque hamstring to quadriceps ratio (h/q ratio) of involved and uninvolved knee flexor strength in the study group. depending on the data distribution, the nonparametric wilcoxon's test or the parametric t-test for the related data was applied. statistical significance was assumed for p\<0.05. the study was approved by our institutional review board. informed consent was obtained and the rights of subjects were protected.

Eligibility criteria:
inclusion criteria: * recurrent patellar dislocation, * correctly completed testing protocol, * age under 18 years at the time of testing exclusion criteria: * osteochondral fracture * those with a history of the knee surgery
enhanced coordinated specialty care for early psychosis

Conditions: Psychosis; Schizophrenia; Schizoaffective Disorder; Psychosis Nos/Other; Bipolar Disorder

Summary: the goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (csc) to five extra care elements (csc 2.0) in first-episode psychosis. the main question it aims to answer is: • does the addition of certain elements of care increase the number of visits in treatment for first-episode psychosis? participants will either: * receive care as usual (csc) or * receive care as usual (csc) plus five additional care elements (csc 2.0): 1. individual peer support 2. digital outreach 3. care coordination 4. multi-family group therapy 5. cognitive remediation researchers will compare the standard of care (csc) to csc 2.0 to see if participants receiving csc 2.0 have more visits to their clinic in their first year.


Eligibility criteria:
inclusion criteria: * people undergoing an intake evaluation to csc for first-episode psychosis in one of the following outpatient clinics: * mclean hospital ontrack (ontrack clinic) * massachusetts general hospital (fepp clinic) * boston medical center (wrap clinic) * cambridge health alliance (rise clinic) * umass memorial health care (step clinic) * servicenet (prep west) exclusion criteria: * none

Keywords: first episode psychosis early psychosis
pilot study of human tear proteins

Conditions: Eye Disease

Summary: the significance of our study is in the importance of understanding the quality and quantity of proteins in the human tear film from diseased and non-diseased patients. this pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.


Eligibility criteria:
inclusion criteria: * 18 years of age and older * able to cooperate with tear sample collection * provide written informed consent exclusion criteria: * special populations (children, pregnant or lactating females, prisoners, etc) * refusal to sign sudy consent

Keywords: ocular proteomics eye disease proteomics
a randomized study of whether alfuzosin(xatral) helps in the passage of kidney stones

Conditions: Kidney Stones

Summary: patients who present for the first time to emergency room with renal colic due to a distal ureteral calculus (as diagnosed with spiral ct scan and kub) will be randomized to receive xatral 10mg po once a day or placebo once discharged from the er. the purpose of this study is to assess if patients treated with xatral will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.


Eligibility criteria:
inclusion criteria: * first presentation to er with renal colic secondary to a distal ureteral stone diagnosed on spiral ct scan * stone radiopaque on kub, distal to the sacro-iliac joint * patient suitable for discharge from er * patient willing to return for follow-up on a weekly basis for maximum 4 visits exclusion criteria: * more than one ureteral calculi * radiolucent stones or cystine stones * prior ipsilateral calculus or ureteral surgery * congenital anomalies of the ureter * patients presents with an absolute indication for intervention * allergy or contraindication to nsaids (history of orthostatic hypotension, current systolic bp \<90 mmhg) * patient currently taking an alpha-blocker * hepatic insufficiency * pregnancy
a study in patients suffering from idiopathic restless legs syndrome who responded to a preceding, 6-month treatment with open-label pramipexole including titration (0.125, 0.25, 0.5, 0.75 mg orally q.n.)

Conditions: Restless Legs Syndrome

Summary: the primary objective is to assess sustained efficacy in patients who have responded to a 6 month treatment with open-label pramipexole. secondary objectives are the measurement of severity of the rls, assessment of early withdrawal phenomena after termination of trial medication, augmentation under treatment, sleepiness, quality of life and subjective wellbeing, the physician's clinical assessment of symptom severity and improvement. another secondary objective is safety and tolerability of treatment.


Eligibility criteria:
inclusion criteria: * male or female out-patients aged 18-80 * diagnosis of idiopathic rls according to the clinical rls criteria of the international rls study group * rlsrs score \> 15 * rls symptoms present at least 2 to 3 days per week within the last 3 months * written informed consent exclusion criteria: * women of childbearing potential without adequate contraception, or breastfeeding * concomitant or previous pharmacologically therapy of rls * clinically significant renal disease, and/or hepatic disease * any of the following lab results at screening: hb, tsh, t3 or t4, clinically significantly out of normal range, positive urine drug screen * other clinically significant metabolic-endocrine (including diabetes mellitus requiring insulin therapy), haematological, gastro-intestinal disease or pulmonary disease . poorly controlled cardiovascular disease * history or clinical signs of peripheral neuropathy (pnp), myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause rls symptoms, history of or clinical signs for any form of epilepsy or seizures * presence of any sleep disorder * history of schizophrenia or any psychotic disorder, history of mental disorders, alcohol abuse or drug addiction * history of or clinical signs of malign neoplasm * patients on a shift-work-schedule, or who are otherwise unable to follow a regular sleep-wake cycle enabling use of study medication at times indicated * allergic to pramipexole or its excipients
speech groups for children living with a sibling who suffers from anorexia nervosa

Conditions: Anorexia Nervosa

Summary: anorexia nervosa (an) is a complex mental disease with a huge impact on the patient's siblings life and well-being. based on literature, group interventions for siblings of children suffering from a chronic disease could provide an effective support. a few have been studied, and even fewer exist for siblings of children with an.

an has a significant impact on nuclear family (parents and siblings). an emerging literature highlights the need for a particular attention to siblings. despite this evidence, research and clinical applications still lack in this area. indeed, most of health services in an offer support for patients, family, parents, but only few specific support for siblings, although positive outcomes of sibling group interventions were reported in other somatic and psychic disabilities. noting the gap between the need and the lack of specific support, the study hypothesis is that the poor diffusion of these interventions in an might result from a low acceptability. the study propose to explore acceptability to adapt and improve group intervention for siblings of children and teenagers receiving care for anorexia nervosa. the study is a mixed-method pilot study assessing the acceptability of a group intervention by including a maximum of 24 siblings of children suffering from an, aged from 8 to 18, across three group sessions, each consisting of 4 meetings. all participants will be invited to fulfill two different auto-questionnaires about their quality of life (before and after group session) and the intervention's acceptability (after group session). quantitative data will be complemented with qualitative data, collected from individual semi-structured interviews with a targeted sampling among group participants.

Eligibility criteria:
* inclusion criteria : sibling presenting a dsm (diagnostic and statistical manual)-5 of mental disorders diagnosis of an, and engaged in inpatient or outpatient healthcare * exclusion criteria : * (1) opposition from the participant and/or from their legal representatives. * (2) non-fluent french speaker * (3) clinical presentation not compatible with the group sessions

Keywords: siblings groups children teenagers acceptability